1.085

9.60% +0.095

After Hours: 1.11 0.025 +2.30%

Biofrontera Inc (BFRI)

Overview News Price History Financials Discussions Forecast Stock Split

Biofrontera Inc stock is currently priced at $1.085, with a 24-hour trading volume of 30,310. It has seen a +9.60% increased in the last 24 hours and a -15.89% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.9833 pivot point. If it approaches the $1.11 resistance level, significant changes may occur.

Previous Close:

$0.99

Open:

$0.982

24h Volume:

30,310

Market Cap:

$5.52M

Revenue:

$34.07M

Net Income/Loss:

$-20.13M

P/E Ratio:

-0.0634

EPS:

-17.1162

Net Cash Flow:

$-24.90M

1W Performance:

+9.60%

1M Performance:

-15.89%

6M Performance:

-64.43%

1Y Performance:

+155.29%

1D Range:

$0.96

$1.10

52W Range:

$0.415

$12.99

Biofrontera Inc Stock (BFRI) Company Profile

Name

Biofrontera Inc

Sector

Healthcare (1204)

Industry

Drug Manufacturers - Specialty & Generic (2)

Phone

781-245-1325

Address

120 Presidential Way, Suite 330, Woburn

Employee

Twitter

Next Earnings Date

2024-06-12

Latest SEC Filings

BFRI's Discussions on Twitter

Biofrontera Inc Stock (BFRI) Latest News

Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 94.9% in May - Defense World

Defense World

$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun ... - Yahoo Finance

Yahoo Finance

Financial Health Report: Biofrontera Inc (BFRI)'s Ratios Tell a Tale – DWinneX - The Dwinnex

The Dwinnex

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper - Simply Wall St

Simply Wall St

Roth Capital Comments on Biofrontera Inc.'s Q2 2024 Earnings (NASDAQ:BFRI) - Defense World

Defense World

Roth Capital Comments on Biofrontera Inc.'s Q2 2024 Earnings (NASDAQ:BFRI) - Defense World

Defense World

Biofrontera Inc Stock (BFRI) Financials Data

Biofrontera Inc (BFRI) Revenue 2024

BFRI reported a revenue (TTM) of $34.07 million for the quarter ending December 31, 2023, a +18.83% rise year-over-year.

Biofrontera Inc (BFRI) Net Income 2024

BFRI net income (TTM) was -$20.13 million for the quarter ending December 31, 2023, a -3,045% decrease year-over-year.

Biofrontera Inc (BFRI) Cash Flow 2024

BFRI recorded a free cash flow (TTM) of -$24.90 million for the quarter ending December 31, 2023, a -53.35% decrease year-over-year.

Biofrontera Inc (BFRI) Earnings per Share 2024

BFRI earnings per share (TTM) was -$12.92 for the quarter ending December 31, 2023, a -1,220% decline year-over-year.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.